COVID-19 death toll passes 75,000 mark. Recently, the World Health Organization states about the increasing number of COVID-19 cases in Africa. If the number of cases continues to rise, the continent’s health systems will become weaker.
Several countries including Kenya, Uganda, and the Republic of the Congo have already imposed countrywide lockdowns. However, people in these countries still have access to essential services. Though, the government must set minimum, uniform standards to address the basic needs of all people.
Members of the editorial board of The Journal of Clinical Endocrinology & Metabolism says that people who use glucocorticoids are at more risk of developing severe symptoms of COVID-19. They explain that glucocorticoids are used for treating chronic inflammatory conditions as they reduce inflammation. But, these drugs can increase the probability of contracting viral infections by curbing the immune system.
Doctors have said that individuals who taking glucocorticoids may develop a high risk of COVID-19. In addition, a new trial found that an antimalarial drug that U.S. President Donald Trump praised may not be effective in treating COVID-19.
“We found no evidence of a strong antiviral activity or clinical benefit of the combination of hydroxychloroquine and azithromycin for the treatment of our hospitalized patients with severe COVID-19,” Jean Michel Molina, from the Infectious Diseases Department at the Saint Louis Hospital, in Paris, France, said.
Molina also added that more randomized clinical trials must be performed to assess the safety and efficacy of this drug combination.